Steven Cohen's TGTX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 365,832 shares of TG Therapeutics, Inc. (TGTX) worth $13.22 M, representing 0.02% of the portfolio. First purchased in 2018-Q1, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2019, adding 675,100 shares. Largest reduction occurred in Q3 2019, reducing 680,155 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2018 | +603,800 | New Buy | 603,800 | $14.20 |
| Q2 2018 | -603,800 | Sold Out | 603,800 | $0.00 |
| Q1 2019 | +1.28 M | New Buy | 1.28 M | $8.04 |
| Q2 2019 | -578,900 | Reduce 45.27% | 700,000 | $8.65 |
| Q3 2019 | -680,155 | Reduce 97.16% | 19,845 | $5.59 |
| Q4 2019 | -19,845 | Sold Out | 19,845 | $0.00 |
| Q3 2022 | +437,200 | New Buy | 437,200 | $5.92 |
| Q4 2022 | -437,200 | Sold Out | 437,200 | $0.00 |
| Q1 2023 | +20,681 | New Buy | 20,681 | $15.04 |
| Q2 2023 | +297,589 | Add 1438.95% | 318,270 | $24.84 |
| Q3 2023 | +293,408 | Add 92.19% | 611,678 | $8.36 |
| Q4 2023 | -611,678 | Sold Out | 611,678 | $0.00 |
| Q2 2024 | +585,873 | New Buy | 585,873 | $17.79 |
| Q3 2024 | -585,873 | Sold Out | 585,873 | $0.00 |
| Q2 2025 | +717,510 | New Buy | 717,510 | $35.99 |
| Q3 2025 | -351,678 | Reduce 49.01% | 365,832 | $36.13 |
Steven Cohen's TG Therapeutics Investment FAQs
Steven Cohen first purchased TG Therapeutics, Inc. (TGTX) in Q1 2018, acquiring 603,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held TG Therapeutics, Inc. (TGTX) for 31 quarters since Q1 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2019, adding 1,278,900 shares worth $10.28 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 365,832 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $13.22 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in TG Therapeutics, Inc. (TGTX) was 1,278,900 shares, as reported at the end of Q1 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.